NasdaqCM:AKBABiotechs
A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data
Akebia Therapeutics (AKBA) just posted third quarter 2025 earnings, swinging from a net loss to net profit as a result of much higher revenue. Investors are watching closely because this marks a financial turnaround for the company.
See our latest analysis for Akebia Therapeutics.
Akebia’s share price has taken a hit recently. Even after swinging to profit this quarter, it fell 18% in the past day and is down 39% over the last month as investors digested mixed clinical trial updates and...